• Robert P Schwartz, Jan Gryczynski, Kevin E O'Grady, Joshua M Sharfstein, Gregory Warren, Yngvild Olsen, Shannon G Mitchell, and Jerome H Jaffe.
• Friends Research Institute, Baltimore, MD 21201, USA. Rschwartz@friendsresearch.org
• Am J Public Health. 2013 May 1;103(5):917-22.

ObjectivesWe examined the association between the expansion of methadone and buprenorphine treatment and the prevalence of heroin overdose deaths in Baltimore, Maryland from 1995 to 2009.MethodsWe conducted a longitudinal time series analysis of archival data using linear regression with the Newey-West method to correct SEs for heteroscedasticity and autocorrelation, adjusting for average heroin purity.ResultsOverdose deaths attributed to heroin ranged from a high of 312 in 1999 to a low of 106 in 2008. While mean heroin purity rose sharply (1995-1999), the increasing number of patients treated with methadone was not associated with a change in the number of overdose deaths, but starting in 2000 expansion of opioid agonist treatment was associated with a decline in overdose deaths. Adjusting for heroin purity and the number of methadone patients, there was a statistically significant inverse relationship between heroin overdose deaths and patients treated with buprenorphine (P = .002).ConclusionsIncreased access to opioid agonist treatment was associated with a reduction in heroin overdose deaths. Implementing policies that support evidence-based medication treatment of opiate dependence may decrease heroin overdose deaths.

24 keywords...

hide…